Cargando…

Use of Novel Biological Agent in Severe Ulcerative Colitis with Poor Response to Initial Therapy: A Case Report

Ulcerative colitis is a condition of chronic inflammation affecting the large intestine. The disease is typically characterized by periods of active inflammation alternating with periods of remission. For patients with moderate to severe ulcerative colitis, the first line for induction therapy optio...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bhandari, Abashesh, Basnet, Bhupendra Kumar
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Journal of the Nepal Medical Association 2022
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9794945/ https://www.ncbi.nlm.nih.gov/pubmed/36705134 http://dx.doi.org/10.31729/jnma.7590

Ejemplares similares

Ulcerative Colitis with Superior Sagittal Sinus Thrombosis: A Case Report
por: Basnet, Somika, et al.
Publicado: (2023)

A Case of Juvenile Polyposis Syndrome in a 13-year-old: A Case Report
por: Bhandari, Abashesh, et al.
Publicado: (2023)

Biological therapy for ulcerative colitis
por: Arora, Zubin, et al.
Publicado: (2015)

Budesonide Foam for Ulcerative Colitis Patients Experiencing Inadequate Response to Biological Therapy
por: Shibuya, Tomoyoshi, et al.
Publicado: (2019)

Potential molecular biomarkers used to predict the response to biological therapies in ulcerative colitis
por: Zhang, Run-Feng, et al.
Publicado: (2021)

Delayed Initiation of Rescue Therapy Associated with Increased Length of Stay in Acute Severe Ulcerative Colitis
por: Caplan, Alyssa, et al.
Publicado: (2022)

Initial experience of tofacitinib for treating refractory moderate-to-severe ulcerative colitis
por: Nakamura, Masanao, et al.
Publicado: (2022)

Best practices on immunomodulators and biologic agents for ulcerative colitis and Crohn’s disease in Asia
por: Ooi, Choon Jin, et al.
Publicado: (2019)

Immune Cells and Transcriptional Signatures Revealed Novel Regulators and Predict Clinical Response to Biologic Therapy in Ulcerative Colitis
por: Savkovic, Suzana D.
Publicado: (2021)

Dual Biological Therapy for Ulcerative Colitis with Intractable Pyoderma Gangrenosum
por: Lee, Hae Chan, et al.
Publicado: (2023)

Efficacy of cytapheresis in patients with ulcerative colitis showing insufficient or lost response to biologic therapy
por: Iizuka, Masahiro, et al.
Publicado: (2022)

Current and Emerging Biologics for Ulcerative Colitis
por: Park, Sung Chul, et al.
Publicado: (2015)

Low Vitamin D Levels in Patients with Irritable Bowel Syndrome of a Tertiary Care Hospital: A Descriptive Cross-sectional Study
por: Bhandari, Abashesh, et al.
Publicado: (2021)

Hyponatremia in Chronic Liver Disease among Patients Presenting to a Tertiary Care Hospital: A Descriptive Cross-sectional Study
por: Bhandari, Abashesh, et al.
Publicado: (2021)

Retrospective Database Analysis: Dose Escalation and Adherence in Patients Initiating Biologics for Ulcerative Colitis
por: Long, Millie D., et al.
Publicado: (2022)

Cost-effectiveness of adalimumab, infliximab or vedolizumab as first-line biological therapy in moderate-to-severe ulcerative colitis
por: Yokomizo, Lauren, et al.
Publicado: (2016)

Severe de novo Ulcerative Colitis following Ixekizumab Therapy
por: Philipose, Jobin, et al.
Publicado: (2018)

New onset severe ulcerative colitis following Ixekizumab therapy
por: Morosanu, Alina Mihaela, et al.
Publicado: (2022)

Acute Severe Ulcerative Colitis: Optimal Strategies for Drug Therapy
por: Nakase, Hiroshi
Publicado: (2023)

Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS)
por: Travis, Simon P L, et al.
Publicado: (2011)

Efficacy of biologic therapies for biologic-naïve Japanese patients with moderately to severely active ulcerative colitis: a network meta-analysis
por: Hibi, Toshifumi, et al.
Publicado: (2021)

Initial diagnosis of Wegener’s granulomatosis mimicking severe ulcerative colitis: a case report
por: Timmermann, Sonja, et al.
Publicado: (2013)

A Challenging Case of Severe Ulcerative Colitis following the Initiation of Secukinumab for Ankylosing Spondylitis
por: Ehrlich, Dean, et al.
Publicado: (2018)

Comparison of the Mayo Endoscopy Score and the Ulcerative Colitis Endoscopy Index of Severity and the Ulcerative Colitis Colonoscopy Index of Severity
por: Belvis Jiménez, María, et al.
Publicado: (2021)

Cutaneous thrombotic vasculopathy related to poorly controlled ulcerative colitis
por: Cheeley, Justin, et al.
Publicado: (2018)

Understanding patient journey in ulcerative colitis prior to biologic initiation: a 5-year exploration
por: Wang, Yiting, et al.
Publicado: (2021)

Biologics for the treatment of pyoderma gangrenosum in ulcerative colitis
por: Arivarasan, K, et al.
Publicado: (2016)

Ulcerative Colitis-Symptom Questionnaire: Valid for Use in Adults with Moderately to Severely Active Ulcerative Colitis
por: Panes, Julian, et al.
Publicado: (2023)

Tofacitinib Response in Ulcerative Colitis (TOUR): Early Response After Initiation of Tofacitinib Therapy in a Real-world Setting
por: Long, Millie D, et al.
Publicado: (2022)

Novel oral-targeted therapies for mucosal healing in ulcerative colitis
por: Antonelli, Elisabetta, et al.
Publicado: (2018)

Cerebral Venous Thrombosis as an Initial Presentation of Ulcerative Colitis
por: Yamazaki, Hiroshi, et al.
Publicado: (2022)

Korean clinical practice guidelines on biologics and small molecules for moderate-to-severe ulcerative colitis
por: Na, Soo-Young, et al.
Publicado: (2023)

Ulcerative colitis immune cell landscapes and differentially expressed gene signatures determine novel regulators and predict clinical response to biologic therapy
por: Penrose, Harrison M., et al.
Publicado: (2021)

Mesalazine-induced myopericarditis in a patient with ulcerative colitis
por: Asadi, Jalal, et al.
Publicado: (2017)

Predictors of Sustained Response With Tofacitinib Therapy in Patients With Ulcerative Colitis
por: Sandborn, William J, et al.
Publicado: (2021)

Impact of biological agents and tofacitinib for moderate-to-severe ulcerative colitis on health-related quality of life: a protocol for a network meta-analysis
por: Ma, Xueni, et al.
Publicado: (2021)

Assessing Severity of Disease in Patients with Ulcerative Colitis
por: Pabla, Baldeep Singh, et al.
Publicado: (2020)

Comparative of the effectiveness and safety of biological agents, small molecule drugs, and microbiome therapies in ulcerative colitis: Systematic review and network meta-analysis
por: Gao, Jie, et al.
Publicado: (2023)

Tofacitinib for ulcerative colitis: results of the prospective Dutch Initiative on Crohn and Colitis (ICC) registry
por: Biemans, Vince B. C., et al.
Publicado: (2020)

Efficacy and Safety of Vedolizumab in Management of Moderate to Severe Ulcerative Colitis: A Systematic Review
por: Bhandari, Renu, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_el04frpo4k45mq8v5l66a6s6u5